Dual GLP-1/glucagon receptor agonist. Combines appetite suppression via GLP-1 with glucagon-mediated increases in energy expenditure and hepatic fat oxidation. Promising for both obesity and NASH/MAFLD.
Inject SubQ once weekly. Titrate: 3mg x4wk → 4.5mg x4wk → 6mg x4wk → 9mg. Monitor liver function. Emerging therapy.
Log doses, calculate reconstitution, set reminders, and get AI guidance for Mazdutide.
Start Free Trial